

Lise M Verhoef

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7056499/publications.pdf>

Version: 2024-02-01

19
papers

435
citations

840776

11
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

645
citing authors

#	ARTICLE	IF	CITATIONS
1	Social Media and Rating Sites as Tools to Understanding Quality of Care: A Scoping Review. <i>Journal of Medical Internet Research</i> , 2014, 16, e56.	4.3	117
2	Is the role as gatekeeper still feasible? A survey among Dutch general practitioners. <i>Family Practice</i> , 2014, 31, 538-544.	1.9	38
3	The disciplined healthcare professional: a qualitative interview study on the impact of the disciplinary process and imposed measures in the Netherlands. <i>BMJ Open</i> , 2015, 5, e009275.	1.9	35
4	bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. <i>Rheumatology and Therapy</i> , 2017, 4, 1-24.	2.3	34
5	Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. <i>The Cochrane Library</i> , 2019, 2019, CD010455.	2.8	33
6	Using Patient Experiences on Dutch Social Media to Supervise Health Care Services: Exploratory Study. <i>Journal of Medical Internet Research</i> , 2015, 17, e7.	4.3	30
7	The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2018, 57, 1947-1955.	1.9	23
8	Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review. <i>Drugs</i> , 2021, 81, 349-366.	10.9	20
9	Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e145-e153.	3.9	19
10	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 403.	1.6	18
11	Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. <i>Trials</i> , 2020, 21, 90.	1.6	14
12	Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. <i>Rheumatology</i> , 2022, 61, 2307-2315.	1.9	14
13	Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1392-1399.	0.9	9
14	Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 439-447.	1.1	7
15	Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab. <i>Rheumatology</i> , 2022, 61, 3974-3980.	1.9	7
16	Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 152-155.	1.1	6
17	Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab002.	0.7	6
18	Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. <i>Rheumatology</i> , 2022, 62, 330-334.	1.9	4

#	ARTICLE	IF	CITATIONS
19	(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges. Rheumatology Advances in Practice, 2021, 5, rkab007.	0.7	1